


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/789,526
		Filing Date	February 26, 2004
		First Named Inventor	George Tachas
		Art Unit	1651
		Examiner Name	Not yet known
Sheet 1 of 4	Attorney Docket Number	23546-08072 (B10L0002US)	



U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
JE	C1	CHEN, N.-Y. et al., <i>A Growth Hormone Antagonist Protects Mice Against Streptozotocin Induced Glomerulosclerosis Even in the Presence of Elevated Levels of Glucose and Glycated Hemoglobin</i> , Endocrinology, Volume 137, No. 11, August 5, 1996, pages 5163-5165.	
JE	C2	COSCHIGANO, K. et al., <i>Assessment of Growth Parameters and Life Span of GHR/BP Gene-Disrupted Mice</i> , Endocrinology, Volume 141, No. 7, February 14, 2000, pages 2608-2613	

Examiner Signature	/Janet Epps Ford/	Date Considered	06/06/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/08072/DOCS/1472159.1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application No.	10/789,526
				Filing Date	February 26, 2004
				First Named Inventor	George Tachas
				Art Unit	1651
				Examiner Name	Not yet known
Sheet	2	of	4	Attorney Docket Number	23546-08072

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
JE	C3	FLYVBJERG, A. et al., <i>Inhibitory Effect of a Growth Hormone Receptor Antagonist (G120K-PEG) on Renal Enlargement, Glomerular Hypertrophy, and Urinary Albumin Excretion in Experimental Diabetes in Mice</i> , Diabetes, Volume 48, 1999, pages 377-382	
JE	C4	FRIEND, K et al., <i>The Growth Hormone Receptor Antagonist Pegvisomant Exhibits Antitumor Activity in Multiple Preclinical Tumor Models</i> , Proceedings of the 200 NCI-EORTC-AACR Symposium, Volume 6 Supplement, November 2000	
JE	C5	FRIEND, K., <i>Cancer and the Potential Place for Growth Hormone Receptor Antagonist Therapy</i> , Growth Hormone & IGF Research 2001, Supplement A, 2001, pages S121-S123	
JE	C6	GRANT, M., <i>The Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy</i> , Diabetes Care, Volume 23, No. 4, April 2000, pages 504-509	
JE	C7	GRONBæk, H. et al., <i>Inhibitory Effects of Octreotide on Renal and Glomerular Growth in Early Experimental Diabetes in Mice</i> , Journal of Endocrinology, Volume 172, 2002, pages 637-643	
JE	C8	HIGGINS, R. et al., <i>Somatostatin Analogs Inhibit Neonatal Retinal Neovascularization</i> , Exp. Eye Res., Volume 74, 2002, pages 553-559	
JE	C9	LANDAU, D. et al., <i>A Novel Somatostatin Analogue Prevents Early Renal Complications in the Nonobese Diabetic Mouse</i> , Kidney International, Volume 60, 2001, pages 505-512	
JE	C10	LeROITH, D. et al., <i>Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor</i> , Endocrine Reviews, Volume 16, No. 2, 1995, pages 143-163	

Examiner Signature	/Janet Epps Ford/	Date Considered	06/06/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/08072/DOCS/1472159.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application No.	10/789,526
				Filing Date	February 26, 2004
				First Named Inventor	George Tachas
				Art Unit	1651
				Examiner Name	Not yet known
Sheet	3	of	4	Attorney Docket Number	23546-08072

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
JE	C11	PARAN, D. et al., <i>A Pilot Study of a Long Acting Somatostatin Analogue for the Treatment of Refractory Rheumatoid Arthritis</i> , Ann. Rheum Dis., Volume 60, 2001, pages 888-891	
JE	C12	PARAN D. et al., <i>Probable Adverse Effects of Long Term Use of Somatostatin Analogues in Patients with RA</i> , Ann Rheum Dis., Volume 61, 2001, page 1117	
JE	C13	PELLEGRINI, E. et al., <i>Central Administration of a Growth Hormone (GH) Receptor mRNA Antisense Increases GH Pulsatility and Decreases Hypothalamic Somatostatin Expression in Rats</i> , Journal of Neuroscience, Volume 16, No. 24, December 15, 1996, pages 8140-8148	
JE	C14	RUBIN, R. et al., <i>Biology of Disease – Insulin-Like Growth Factor-I Receptor: Its Role in Cell Proliferation, Apoptosis, and Tumorigenicity</i> , Laboratory Investigation, Volume 73, No. 3, 1995, pages 311-331	
JE	C15	SEGEV, Y. et al., <i>Growth Hormone Receptor Antagonism Prevents Early Renal Changes in Nonobese Diabetic Mice</i> , J. Am., Soc. Nephrol., Volume 10, 1999, pages 2374-2381	
JE	C16	SERRI, O. et. al., <i>Somatostatin Analogue, Octreotide, Reduces Increased Glomerular Filtration Rate and Kidney Size in Insulin-Dependent Diabetes</i> , JAMA, Volume 265, No. 7, February 20, 1991, pages 888-892	
JE	C17	SJÖGREN, K. et al., <i>Liver-Derived Insulin-Like Growth Factor I (IGF-I) is the Principal Source of IGF-I in Blood But is Not Required for Postnatal Body Growth in Mice</i> , Proc. Natl. Acad. Sci. USA, Volume 96, June 1999, pages 7088-7092	
JE	C18	SMITH, L. et al., <i>Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization</i> , Science, Volume 276, June 13, 1997, pages 1706-1709	

Examiner Signature	/Janet Epps Ford/	Date Considered	06/06/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/08072/DOCS/1472159.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application No.	10/789,526
				Filing Date	February 26, 2004
				First Named Inventor	George Tachas
				Art Unit	1651
				Examiner Name	Not yet known
Sheet	4	of	4	Attorney Docket Number	23546-08072

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
JE	C19	TRAINER, P. et al., <i>Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant</i> , The New England Journal of Medicine, Volume 342, No. 16, April 20, 2000, pages 1171-1177	
JE	C20	TURNLEY, A. et al., <i>Suppressor of Cytokine Signaling 2 Regulates Neuronal Differentiation by Inhibiting Growth Hormone Signaling</i> , Nature Neuroscience, Volume 5, No. 11, November 2002, pages 1155-1162	
JE	C21	ULLRICH, A., et al., <i>Insulin-like Growth Factor I Receptor Primary Structure: Comparison with Insulin Receptor Suggests Structural Determinants that Define Functional Specificity</i> , EMBO J., Volume 5, July 18, 1986, pages 2503-2512	
JE	C22	VAN DER LELY, A., et al., <i>Long-Term Treatment of Acromegaly with Pegvisomant, A Growth Hormone Receptor Antagonist</i> , The Lancet, Volume 358, November 24, 2001, pages 1754-1759	
JE	C23	VAN NECK, J., et al., <i>Dose-Response Effects of a New Growth Hormone Receptor Antagonist (B2036-PEG) on Circulating, Hepatic and Renal Expression of the Growth Hormone/Insulin-Like Growth Factor System in Adult Mice</i> , Journal of Endocrinology, Volume 167, 2000, pages 295-303	

Examiner Signature	/Janet Epps Ford/	Date Considered	06/06/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/08072/DOCS/1472159.1